AARD - NOTRELOAD AI

AARD/ 02/27/2026 · 4:25 PM

Aardvark Therapeutics Pauses Phase 3 HERO Trial for PWS Hunger Drug ARD-101 Over Safety Signals

Aardvark Therapeutics voluntarily pauses Phase 3 HERO trial of ARD-101 for Prader-Willi hyperphagia after reversible cardiac signals in high-dose study. Updates expected Q2 2026.

AARD/ 12/23/2025 · 7:44 AM

Oppenheimer Starts Coverage on Aardvark Therapeutics with Strong Rating

Oppenheimer analyst gives Aardvark Therapeutics an Outperform rating with $35 price target, highlighting rare and common obesity drug programs and a key Phase 3 trial.

AARD/ 12/02/2025 · 4:40 PM

Raymond James Starts Coverage of Aardvark Therapeutics With Strong Buy Rating

Raymond James initiates Aardvark Therapeutics with a Strong Buy and a $47 price target, highlighting strong Phase 2 data for ARD-101 and unmet needs in hyperphagia treatment.

#AARD↓

Aardvark Therapeutics Pauses Phase 3 HERO Trial for PWS Hunger Drug ARD-101 Over Safety Signals

Oppenheimer Starts Coverage on Aardvark Therapeutics with Strong Rating

Raymond James Starts Coverage of Aardvark Therapeutics With Strong Buy Rating